U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07734610) titled 'A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)' on July 20.
Brief Summary: The purpose of this study is to learn what happens to nemtabrutinib in a person's body when given to participants with severe kidney disease and to healthy participants.
Study Start Date: Aug. 17
Study Type: INTERVENTIONAL
Condition:
Severe Renal Impairment
Healthy
Intervention:
DRUG: Nemtabrutinib
Oral administration
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Merck Sharp & Dohme LLC
Published by HT Digital Content Services with permission from Health Daily Digest....